Barinthus Biotherapeutics plc

2.94 USD
-0.10 (-3.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Barinthus Biotherapeutics plc stock is down -30.66% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 November’s closed higher than October. 100% of analysts rate it a buy.

About Barinthus Biotherapeutics plc

Vaccitech plc engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the. treatment of chronic hepatitis B infection; VTP -200, which has completed Phase 1 clinical trials for human papilloma virus infection. Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection, is in preclinical stage.